PFM Health Sciences’s Integra LifeSciences IART Stock Holding History

PFM Health Sciences’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-295,257	Closed	-$7.44M	–	101
2015 Q1	$7.44M	Buy	+295,257	New	+$6.98M	0.21%	75

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PFM Health Sciences's IART Position: Q2 2015 in Review

PFM Health Sciences sold out of Integra LifeSciences (IART) in Q2 2015, closing a stake of 295,257 shares — an estimated $7.44M sold.

PFM Health Sciences first reported a position in IART in Q1 2015 and held it in 1 quarter. The position peaked at $7.44M in Q1 2015. 186 funds tracked by Wall St. Rank hold IART as of Q2 2015.

PFM Health Sciences reported no remaining Integra LifeSciences position as of Q2 2015 after selling out during the quarter.
PFM Health Sciences sold 295,257 Integra LifeSciences shares in Q2 2015, an estimated $7.44M.
PFM Health Sciences first reported a position in Integra LifeSciences in Q1 2015 and held it in 1 quarter.
PFM Health Sciences's Integra LifeSciences position peaked at $7.44M in Q1 2015.
186 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2015.

Based on PFM Health Sciences's 13F filing for Q2 2015, filed 14 Aug 2015.